title: Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression.
abstract: OBJECTIVE
  The aim of this study is to determine when during hematopoiesis Siglec-8 gets expressed, whether it is expressed on hematologic malignancies, and if there are other non-human species that express Siglec-8.
  
  
  METHODS
  Siglec-8 mRNA and cell surface expression was monitored during in vitro maturation of human eosinophils and mast cells. Flow cytometry was performed on human blood and bone marrow samples, and on blood samples from dogs, baboons, and rhesus and cynomolgus monkeys.
  
  
  RESULTS
  Siglec-8 is a late maturation marker. It is detectable on eosinophils and basophils from subjects with chronic eosinophilic leukemia, chronic myelogenous leukemia, and on malignant and non-malignant bone marrow mast cells, as well as the HMC-1.2 cell line. None of the Siglec-8 monoclonal antibodies tested recognized leukocytes from dogs, baboons, and rhesus and cynomolgus monkeys.
  
  
  CONCLUSIONS
  Siglec-8-based therapies should not target immature human leukocytes but should recognize mature and malignant eosinophils, mast cells, and basophils. So far, there is no suitable species for preclinical testing of Siglec-8 monoclonal antibodies.
authors.affiliation: Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
authors.forename: Sherry A
authors.initials: SA
authors.lastname: Hudson
authors.forename: Harald
authors.initials: H
authors.lastname: Herrmann
authors.forename: Jian
authors.initials: J
authors.lastname: Du
authors.forename: Paul
authors.initials: P
authors.lastname: Cox
authors.forename: El-Bdaoui
authors.initials: el-B
authors.lastname: Haddad
authors.forename: Barbara
authors.initials: B
authors.lastname: Butler
authors.forename: Paul R
authors.initials: PR
authors.lastname: Crocker
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Ackerman
authors.forename: Peter
authors.initials: P
authors.lastname: Valent
authors.forename: Bruce S
authors.initials: BS
authors.lastname: Bochner
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000378:metabolism; D015703:Antigens, CD / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D000944:Antigens, Differentiation, B-Lymphocyte / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D001491:Basophils / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D001853:Bone Marrow / Q000473:pathology; D002460:Cell Line; D002469:Cell Separation; D004285:Dogs; D004804:Eosinophils / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D005260:Female; D005434:Flow Cytometry; D018507:Gene Expression Regulation, Developmental; D015972:Gene Expression Regulation, Neoplastic; D000882:Haplorhini; D006410:Hematopoiesis / Q000276:immunology; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000276:immunology* / Q000473:pathology; D037102:Lectins / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D007951:Leukemia, Myeloid / Q000276:immunology* / Q000473:pathology; D008297:Male; D008407:Mast Cells / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D008875:Middle Aged; D013045:Species Specificity
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000944:Antigens, Differentiation, B-Lymphocyte; D037102:Lectins; C403967:SIGLEC8 protein, human